Merck Whistleblower Case Proceeds Toward a Resolution
As the Merck MMR whistle blower case proceeds toward a resolution that increasingly appears to spell doom for Merck’s scandal ridden MMRII blockbuster, U.S. Department of Health and Human Services (DHHS) officials are scrambling to get Glaxo’s version of the MMR teed up to fill the coming vacuum.
Recap: Two senior Merck scientists, Stephen Krahling and Joan Wlochowski, filed their Federal whistleblower lawsuit in 2010 claiming Merck fraudulently added rabbit antibodies to human blood samples to gull FDA officials into believing the vaccine 95% effective and thereby win an MMR monopoly. When the scientists threatened to expose the fraud, Merck officials offered bribes, threatened them with prison and then destroyed the laboratory evidence in garbage bags.
Merck’s defective MMRII is currently causing dangerous Mumps epidemics in fully vaccinated adults across the globe. At FDA’s behest (GSK) recently published the results of US clinical trials for the hasty licensing of Glaxo’s (MMR) vaccine Priorix® (Klein et al. 2019). Knowing that no MMR can survive safety testing against an inert placebo, FDA allowed GSK to test Priorix against Merck’s MMR II. The results were so horrifying for both vaccine formulations that Glaxo and FDA decided against publishing them in the main paper burying them instead in a supplemental table within an addendum.
Table 6 displays the shocking results; Nearly 50% of vaccine recipients experienced adverse events within 42 days of vaccination and over 10% of these required emergency room visits. Roughly 2% of these adverse events were “serious” and 3.5% of vaccine recipients were diagnosed with a “new onset chronic disease” within 6 months of vaccination. These documented safety results are astronomically higher than the vaccine industry talking points which claim vaccine adverse events are “one-in-a-million”. They are much more in line with the results of the DHHS’s Lazarus study where 1 in 39 vaccine recipients showed an adverse reaction.